Please provide your email address to receive an email when new articles are posted on . The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ...

Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

(RTTNews) - KALA BIO Inc. (KALA) is in focus, as anticipation builds around its upcoming clinical trial data for KPI-012, a novel stem cell-derived therapy targeting persistent corneal epithelial ...

KALA BIO completes patient enrollment in CHASE trial, evaluating KPI-012 for treating persistent corneal epithelial defect, with results due Q3 2025. KALA BIO, Inc. announced the completion of patient ...

In this figure you can see all of the diseases that were identified linked to epithelial barrier defect and microbial dysbiosis linked to epithelial barrier damaging environmental substances In this ...

Sterile infiltrates following collagen crosslinking (CXL) are an uncommon complication, typically reported in the early postoperative period. A patient in her mid-20s was diagnosed with keratoconus ...

Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...